Updates from the 2022 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 300 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific…
ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Plus Venetoclax Investigators reported updated results from a phase II trial exploring the use of ibrutinib-venetoclax combination therapy in patients with high-risk…
ASH 2022: Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy Consolidation with either whole-brain radiation therapy (WBRT) or autologous stem cell transplant (autoSCT) improves overall survival in patients with primary central nervous system lymphoma (PCNSL), regardless of first-line…
ASH 2022: Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Combination therapy with rituximab (Rituxan) and lenalidomide (Revlimid) was approved for use in relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) based on the results…
ASH 2022: Updated Index Improves Prognostication for Survival in Advanced-Stage Hodgkin Lymphoma Models that have historically been used to predict survival outcomes in advanced-stage classical Hodgkin lymphoma (A-HL) are outdated and less useful in the modern treatment era. Members of…
ASH 2022: Next-Generation BTKi Zanubrutinib Demonstrates Improved Efficacy and Tolerability Compared with Ibrutinib The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib (Imbruvica) has become the standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) but can cause…
ASH 2022: Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma In research presented by Nancy Bartlett, MD, a past Scientific Advisory Board (SAB) member and LRF grantee, durable clinical responses were observed in patients with relapsed/refractory follicular lymphoma…
ASH 2022: Quality of Life Improves Quickly in Survivors of Aggressive Lymphomas Lymphomas are a potentially curable subset of cancers, but long-term treatment or disease effects may impact quality of life. Researchers, therefore, sought to determine how quality of life…
ASH 2022: Short-course Brentuximab Vedotin with Chemotherapy is Highly Active in Early-Stage Bulky Hodgkin LymphomaASH 2022 Treatment with short-course brentuximab vedotin (Adcetris; BV), an antibody-drug conjugate, combined with chemotherapy in early-stage, bulky Hodgkin lymphoma (HL) was associated with four-year overall…
Where Are They Now? Deborah Stephens, DO When did you become interested in the study of medicine? In lymphoma specifically? I grew up on a farm, and my mom told me she knew I would go into medicine because I…
